March 22-26, 2015
San Diego, CA
“AOPs 201”: A Seminar on Development, Recording, and Use of Adverse Outcome Pathways
Monday, March 23, 5:00 PM–7:30 PM
San Diego Marriott Marquis & Marina
333 West Harbor Drive
San Diego, CA
Marina Ballroom F
Building on progress since a successful “AOPs 101” seminar at the Society of Toxicology meeting in 2014, the Human Toxicology Project Consortium and the Physicians Committee for Responsible Medicine invite you to learn a bit more about Adverse Outcome Pathways and the tools and guidance that are available to help you develop and record them. Case studies of AOPs in various stages of development will be presented to demonstrate the major steps one would take in developing an AOP. Click here for full program.
FutureTox III: Transforming 21st Century Science into Risk Assessment and Regulatory Decision-Making
November 19–20, 2015
- Threshold of Toxicological Concern – an approach for safety assessment and its applicability to cosmetics-related chemicals | Chihae Yang, Altamira, LLC and Molecular Networks
- Medical Device Irritation Testing: An In Vitro Alternative | Kelly Coleman, Medtronic Biomaterials Dept
- Developing Confidence in 21st-Century Risk Assessments | Craig Rowlands, Dow Chemical Company
- COSMOS DB: A New Database of Toxicological Information to Support Knowledge Discovery | Mark Cronin, Liverpool John Moores University and COSMOS project coordinator
- High Content Imaging Approaches in Neurotoxicology and Neurodegeneration Research | Marcel Leist, University of Konstanz and CAAT Europe
- EURL ECVAM's Approach to Validation of Alternative Methods | Valerie Zhuang, EURL ECVAM
- Using the AOP Framework to Develop HTS Assays for Thyroid-Disrupting Chemicals | Katie Paul, US EPA
- The Role of Non-Animal Methods in the Regulation of Nanomaterials in the United States | Erik Janus, Steptoe and Johnson LLP (Recording not available)
- Human Induced Pluripotent Stem Cell-derived Model Systems | Maureen Bunger, Cellular Dynamics
- Incorporating New Technologies into Toxicity Testing and Risk Assessment | Russell Thomas, The Hamner Institutes for Health Science
- The Virtual Embryo | Nicole Kleinstreuer, US EPA
- Tox21 Program Update | Raymond Tice, National Toxicology Program, NIH
- Evidence-Based Toxicology (EBT) for the 21st Century | Martin Stephens, Johns Hopkins University
- Effectopedia: The Online Encyclopedia of Adverse Effect Pathways | Gilman Veith and Hristo Aladjov, International QSAR Foundation
- MetaPath: A Metabolism Pathway Database | Patricia Schmeider, US EPA
Second Annual Scientific Meeting of the American Society for Cellular and Computational Toxicology: The Future Is Here: Practical Applications of Emerging Scientific Tools
Human Organs on Chips as Replacements for Animal Testing, the keynote address given by Donald E. Ingber, M.D., Ph.D., of the Wyss Institute at Harvard, kicked off the meeting which featured a dozen lectures and poster presentations on making toxicology a more human-relevant science. Other topics included methods to replace live animals in eye irritation tests and computer-based virtual embryos that show how chemical exposures might affect developing embryos. View Program. ASCCT members, click here to view select presentations.
First Annual Scientific and Business Meeting of the ASCCT
The first annual ASCCT meeting focused on advances in the fields of in vitro and computational toxicology. Dr. Melvin Andersen, associate director of The Institute for Chemical Safety Sciences at The Hamner Institutes for Health Sciences and ASCCT board member, gave a plenary lecture on Computational Cellular Pathway Modeling: Combining Key In Vitro and In Silico Tools to Enhance Modern Safety Assessment. Dr. Suzanne Fitzpatrick, senior advisor for toxicology at the U.S. Food and Drug Administration gave a plenary lecture on an Overview of the FDA-DARPA-NIH Collaboration on Human/Organ on a Chip.
Institute for In Vitro Sciences Practical Methods for In Vitro Toxicology Workshop
Attendees gained hands-on laboratory experience and instruction in the practical application of the lectured topics. Topics for the three and a half day course included: (i) international regulatory acceptance status of in vitro assays, (ii) predicting organ specific toxicity (e.g., ocular, dermal and hepatic), (iii) using cell and organ culture models with histological, biochemical, and molecular endpointsm, and (iv) data interpretation.
2010 In Vitro Alternatives Forum
Thank you for contributing to a successful forum. Read the post-meeting report.
8th World Congress for Alternatives and Animal Use
Thank you for helping to make the ASCCT/ESTIV luncheon session a success. A manuscript outlining the discussions that took place during the session has been published. You can view the entire proceedings here.